Risk Factors for Venous Thromboembolism
VTE results from a complex interplay between patient-related (usually permanent) and setting-related (usually temporary) risk factors, with the most critical being advanced age, active malignancy, major surgery/trauma, hospitalization, immobilization, prior VTE history, and inherited thrombophilias. 1
Patient-Related (Usually Permanent) Risk Factors
Demographic Factors
- Age: Risk increases dramatically with age—before age 40, risk is approximately 1 in 10,000 persons per year, escalating to 1 in 100 persons per year after age 75 1
- Male sex: Associated with higher VTE risk and increased recurrence rates 1
Genetic/Inherited Thrombophilias
The most common genetic predispositions include:
- Factor V Leiden (FVL): Present in approximately 5.1% of non-Hispanic whites, 2.0% of Hispanic whites, and 1.2% of African Americans 2
- **Prothrombin G20210A (Factor II c.*97G>A)**: Second most common genetic mutation 1
- Deficiencies in natural anticoagulants: Antithrombin III, Protein C, and Protein S (account for 5-10% of thrombosis cases and have more quantifiable VTE association) 1
Critical caveat: Genetic factors are present in only 25% of screening populations without family history and up to 63% of familial cases. Approximately 50% of first-time VTE cases are unprovoked, meaning no clear risk factor is identified 1.
Medical Comorbidities
- Obesity: Body mass index ≥35 kg/m² increases risk 3
- Diabetes 4
- Cardiac conditions: Heart failure, atrial fibrillation 4
- Chronic respiratory failure 4
Prior VTE History
History of previous VTE is one of the strongest independent risk factors, with recurrence rates of approximately 20% within 5 years and 30% within 10 years after the first event 1. In cancer patients, 12-month cumulative recurrence reaches 20.7% compared to 6.8% in non-cancer patients 4.
Setting-Related (Usually Temporary) Risk Factors
Hospitalization and Critical Illness
- Hospitalization alone: Increases VTE risk 8-fold 5
- Critical illness: Strongly associated with VTE (up to 20% incidence in ICU patients) 6
- Hospital or nursing home confinement: OR 8.0 (95% CI: 4.5-14.2) 7
Surgical and Trauma-Related
The strongest provoking factors include:
- Major surgery: OR 21.7 (95% CI: 9.4-49.9) 8, 7
- Major trauma: OR 12.7 (95% CI: 4.1-39.7) 7
- Hip fracture and lower extremity fractures 8
- Spinal cord injury with paralysis 8
- Length of anesthesia 3
Immobilization
- Prolonged immobilization: Includes bed rest, prolonged travel 1
- Acute paresis/neurological disease with extremity paresis: OR 3.0 (95% CI: 1.3-7.4) 5, 7
- Lower Barthel Index score (indicating reduced functional status) 6
Malignancy-Related Factors
Cancer increases VTE risk 4- to 7-fold, with the highest risk in:
- Very high-risk cancers (risk score 2): Pancreatic and gastric adenocarcinoma 3, 8
- High-risk cancers (risk score 1): Lung, hematological malignancies, brain tumors, gynecological, bladder, testicular 3, 4, 8
- Metastatic disease: OR 19.8 for solid tumors with distant metastases 4
Chemotherapy-specific factors 3:
- Chemotherapy increases risk through vessel wall damage, endothelial injury, decreased natural anticoagulants, and platelet activation
- Antiangiogenic agents (bevacizumab, thalidomide, lenalidomide): 33% relative increase in VTE risk; overall incidence 11.9% (any-grade) and 6.3% (high-grade) 3
- Thalidomide plus doxorubicin: VTE rates up to 34% in multiple myeloma 3
Additional cancer-related factors:
- Central venous catheter or pacemaker: OR 5.6 (95% CI: 1.6-19.6) 7
- Extrinsic vascular compression from bulky lymphadenopathy 4
Hematological Abnormalities
- Prechemotherapy platelet count ≥350,000/µL (risk score 1) 3
- Prechemotherapy leukocyte count >11,000/µL (risk score 1) 3, 6
- Hemoglobin <10 g/dL or use of erythropoiesis-stimulating agents (risk score 1) 3, 4
- Elevated D-dimer levels: OR 2.46 (95% CI: 1.37-4.40) 6, 9
- Elevated C-reactive protein and fibrinogen 6
- Thrombocytosis, tachycardia, fever 6
Infection
Acute infection is a critical and often underrecognized risk factor:
- Increases VTE risk 3-fold within the first 3 months after infection 4
- In cancer patients, infection is a major predictor of VTE hospitalization 4
- This factor is notably absent from many widely used risk assessment models 5
Hormone-Related Factors
For women of reproductive age and postmenopausal women:
- Combined oral contraceptives: 2- to 6-fold increase in VTE risk over baseline 8
- Pregnancy and postpartum period 1
- Estrogen replacement therapy 1
- Tamoxifen and raloxifene treatment (in breast cancer patients) 1
Other Acquired Factors
- Blood transfusions: Significant risk factor, especially in cancer patients 4
- Superficial vein thrombosis: OR 4.3 (95% CI: 1.8-10.6) 7
- Varicose veins: Risk diminishes with age (OR 4.2 at age 45 vs. 0.9 at age 75) 7
- Invasive mechanical ventilation: OR 2.08 (95% CI: 1.46-2.96) 9
- Central venous catheterization: OR 2.67 (95% CI: 1.67-4.28) 9
Risk Stratification for Ambulatory Cancer Patients
The Khorana score provides validated risk stratification 3:
- Low risk (score 0): 0.3-0.5% VTE incidence
- Intermediate risk (score 1-2): 2% VTE incidence
- High risk (score ≥3): 6.7-7% VTE incidence
Important Clinical Pitfalls
Approximately 50% of first-time VTE cases appear unprovoked, meaning no obvious risk factor is identified despite thorough evaluation 1
Risk factors act synergistically: Most patients with VTE have multiple risk factors present simultaneously, including up to half of those with genetic predisposition 2
Acute infection is frequently overlooked as a VTE risk factor and is not included in most widely used risk assessment models 5
Not all inherited thrombophilias carry equal risk: Factor V Leiden and prothrombin mutations were NOT associated with increased VTE risk in cancer patients receiving chemotherapy 4
Liver disease paradoxically reduces VTE risk: OR 0.1 (95% CI: 0.0-0.7) 7